Project Grant R01AR084248

Award Date 8/1/24
Completion Date 7/31/29
Dollars Obligated $1.1M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
New York, NY 10021, USA
Similar Awards
This Project Grant award of $1,150,474 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to explore the cellular and molecular mechanisms driving large-scale bone regeneration. The research aims to unravel the intricate events necessary for extensive bone repair by investigating the role of a sentinel-type cell population marked by SOX9 expression in...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $412,756 to The University of Texas Southwestern Medical Center to conduct research on the mechanisms regulating bone healing and angiogenesis in osteonecrosis. The research aims to identify and define the critical Osterix-positive progenitor cell population responsible for the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $588,302 to The University of Texas Southwestern Medical Center (UT Southwestern) to conduct research on the metabolic regulation of osteoclast differentiation and bone resorption. The key objectives are to: 1) establish the necessity and sufficiency of glutaminase (GLS) dependent...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $465,663 to optimize the bone surface targeting of therapeutic antibodies for the treatment of osteoporosis. The key objectives are to: 1) Optimize the pharmacokinetics and pharmacodynamics of an anti-sclerostin antibody in healthy and ovariectomy-induced osteoporosis animal models, and...
This $222,500 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research at The Children's Hospital of Philadelphia (CHOP) to investigate the pathogenic mechanisms of temporomandibular joint (TMJ) osteophyte formation. The key objectives are to test whether conditional ablation of the gene EXT1, which is involved in heparan sulfate synthesis, causes osteophyte formation...
This Project Grant award, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to resolve the mechanism of osteoclast multinucleation and signaling in bone remodeling. The $249,000 award to the Rector & Visitors of the University of Virginia will fund a 3-year research project to: 1) identify the domain of the lupus La protein that regulates osteoclast...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $688,634.00 in funding to The Hospital For Special Surgery Fund, Inc. (dba HSS Foundation) from December 1, 2024 to November 30, 2029. The award supports research to investigate the mechanisms by which the constitutive type-I interferon (IFN-I) response suppresses osteoblastogenesis and bone formation, especially in the context of inflammatory conditions like rheumatoid...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $513,574 to the Regents of the University of Michigan to study the mechanisms that lead to osteonecrosis of the jaw (ONJ) in patients taking anti-resorptive medications. The researchers aim to elucidate the cellular and genetic factors that contribute to ONJ, and develop a polygenic risk score to predict susceptibility to...
This Project Grant award of $226,500.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to define how oral pathogens affect aging-associated immune responses and whether inhibition of the CD38 signaling pathway can attenuate inflammatory bone loss and alleviate aging-associated immune responses induced by oral pathogens. The research will be conducted by the Medical University of...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $667,125 to the University of Massachusetts Medical School (UMass Medical) to develop a long-lasting, bone-targeted gene therapy for treating osteogenesis imperfecta (OI), the most common bone fragility disease. The project aims to enhance bone-forming signaling pathways in OI patients by...

NEGATIVE REGULATION OF OSTEOCLASTOGENESIS - MANY PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESSIVE BONE LOSS ARE CHARACTERIZED BY INCREASED GENERATION OF OSTEOCLASTS, MYELOID LINEAGE CELLS THAT RESORB BONE. THE LONG TERM GOALS OF THIS PROJECT ARE TO ELUCIDATE MOLECULAR PATHWAYS AND MECHANISMS THAT REGULATE MYELOID CELL FUNCTION AND OSTEOCLASTOGENESIS UNDER PATHOLOGICAL INFLAMMATORY CONDITIONS, WITH THE ASSOCIATED GOAL OF USING THIS INFORMATION TO DEVELOP NEW THERAPEUTIC APPROACHES TO SUPPRESS PATHOLOGICAL BONE RESORPTION. INFLAMMATION IS AN IMPORTANT DRIVER OF PATHOLOGICAL BONE LOSS IN DISEASES SUCH AS RHEUMATOID ARTHRITIS AND INFECTIONS. PATHOLOGICAL INFLAMMATION-ASSOCIATED BONE LOSS IS RESISTANT TO STANDARD ANTI-RESORPTIVE THERAPIES; THUS, DEVELOPMENT OF NEW TREATMENTS REPRESENTS AN IMPORTANT UNMET MEDICAL NEED. IN THE PREVIOUS CYCLE OF THIS APPLICATION, WE DEFINED EPIGENETIC AND METABOLIC MECHANISMS BY WHICH INFLAMMATORY CYTOKINES, INTERFERON- (IFN-) AND HYPOXIA REGULATE OSTEOCLASTOGENESIS. WE TESTED THE PATHOPHYSIOLOGICAL IMPORTANCE OF THESE MECHANISMS IN MODELS OF INFLAMMATORY BONE LOSS INCLUDING ARTHRITIS, IMPLANT LOOSENING, SUPRACALVAREAL OSTEOLYSIS, AND ORTHOPEDIC PERIPROSTHETIC JOINT INFECTION (PJI). PJI IS A DEVASTATING COMPLICATION OF JOINT REPLACEMENT SURGERY THAT IS RESISTANT TO TREATMENT AND A MAJOR CAUSE OF MORBIDITY, AND EVEN MORTALITY, IN ORTHOPEDICS. ONE ASPECT OF PJI IS BIOFILM-ASSOCIATED INFECTION AT THE BONE- IMPLANT INTERFACE WHICH RESULTS IN BOSS LOSS AND IMPLANT LOOSENING. USING A CLINICALLY RELEVANT TIBIAL IMPLANT MODEL OF PERSISTENT BIOFILM-ASSOCIATED STAPHYLOCOCCUS AUREUS PJI, WE OBSERVED BONE LOSS AND FAILURE OF OSSEOINTEGRATION. THIS WAS ASSOCIATED WITH SUSTAINED INFLAMMATION AT SITES OF INFECTION, BUT ADAPTIVE IMMUNE T CELLS WERE SUPPRESSED. ADVANCING THE LITERATURE DEMONSTRATING MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS) THAT SUPPRESS T CELLS IN S. AUREUS INFECTIONS, WE NEWLY IDENTIFIED EXPRESSION OF INHIBITORY GENES IN THE SETTING OF A STRONG IFN- SIGNATURE, AN OSTEOCLASTOGENIC PROGRAM SELECTIVELY AT THE BONE-IMPLANT INTERFACE, AND ALTERED MYELOPOIESIS IN THE DISTAL BONE MARROW. INHIBITORY GENE EXPRESSION WAS MARKEDLY HIGHER IN TISSUE ADJACENT TO THE IMPLANT AND BIOFILM, RELATIVE TO SOFT TISSUES INFECTED WITH PLANKTONIC PHASE S. AUREUS. BASED ON THESE RESULTS, OUR OVERARCHING HYPOTHESIS IS THAT S. AUREUS PJI INFECTION INDUCES SUSTAINED INFLAMMATION THAT DRIVES OSTEOCLASTOGENESIS, BUT CONCOMITANTLY INDUCES FEEDBACK INHIBITORY MECHANISMS THAT SUPPRESS ADAPTIVE IMMUNITY AND ATTENUATE CLEARANCE OF INFECTION, RESULTING IN SUBSTANTIAL MORBIDITY. WE PROPOSE THAT GREATER UNDERSTANDING OF THE INFLAMMATORY AND BONE MARROW RESPONSES THAT DRIVE OSTEOCLASTOGENESIS, AND OF FEEDBACK MECHANISMS THAT SUPPRESS THE ADAPTIVE IMMUNE RESPONSE TO PJI, WILL PROVIDE KNOWLEDGE THAT CAN BE USED TO DEVELOP NEW APPROACHES TO SUPPRESS PATHOLOGIC BONE RESORPTION AND TO DEVELOP ADJUVANT IMMUNOTHERAPIES TO HELP CLEAR THIS DEVASTATING CONDITION.

Posted 7/23/24, 12:00 AM